Pharmacological Synergy: The Next Frontier for Migraine
Pharmacological Synergy: The Next Frontier for Migraine
As more new migraine treatments are developed, the possibility of developing combination treatments increases. Currently, the combination of sumatriptan and naproxen (marketed as Treximet®) is the only FDA-approved combination treatment for migraine. Rational polytherapy addressing the multiple mechanisms of migraine, however, opens up many new possibilities for the development of both acute and preventive migraine therapies. In determining the efficacy of these potential combination treatments, synergy should be included in this assessment. Another potential benefit of combination treatments is increased patient compliance because multiple medications can be contained in one formulation.
The combination of sumatriptan and naproxen is the only migraine treatment to date for which statistically significant synergy has been demonstrated. The statistical method outlined in this article could be used to assess many other potential combination treatments. This may allow for more effective treatment development and fill the need for more migraine treatments.
Conclusions
As more new migraine treatments are developed, the possibility of developing combination treatments increases. Currently, the combination of sumatriptan and naproxen (marketed as Treximet®) is the only FDA-approved combination treatment for migraine. Rational polytherapy addressing the multiple mechanisms of migraine, however, opens up many new possibilities for the development of both acute and preventive migraine therapies. In determining the efficacy of these potential combination treatments, synergy should be included in this assessment. Another potential benefit of combination treatments is increased patient compliance because multiple medications can be contained in one formulation.
The combination of sumatriptan and naproxen is the only migraine treatment to date for which statistically significant synergy has been demonstrated. The statistical method outlined in this article could be used to assess many other potential combination treatments. This may allow for more effective treatment development and fill the need for more migraine treatments.
Source...